Dogwood Therapeutics (DWTX) Stock Price, News & Analysis

Company Overview

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients. Its preclinical pipeline includes antibody and protein candidates targeting key inflammatory and fibrotic pathways. In addition to cardiovascular indications, the company is evaluating opportunities in liver and renal fibrosis, with plans to advance multiple programs into IND‐enabling studies over the coming year.

Founded in 2021 and headquartered in Vancouver, British Columbia, Dogwood Therapeutics also maintains research operations in Boston, Massachusetts. The company works in collaboration with academic institutions and clinical research organizations across North America to support its development efforts. Led by an experienced management team with backgrounds in biologics discovery and cardiovascular drug development, Dogwood is positioning itself to address significant unmet needs in fibrotic disease.

Key Stats

• Today's Range: $4.77 to $4.93
• 50-Day Range: $4.50 to $5.30
• 52-Week Range: $1.62 to $29.28
• Volume: 7,696 shs
• Average Volume: 13,646 shs
• Market Capitalization: $9.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Dogwood Therapeutics Stock Analysis - MarketRank™

Dogwood Therapeutics scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Dogwood Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Dogwood Therapeutics has a consensus price target of $10.00, representing about 105.8% upside from its current price of $4.86.

Amount of Analyst Coverage

Dogwood Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Dogwood Therapeutics are expected to grow in the coming year, from ($6.43) to ($4.57) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dogwood Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dogwood Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for DWTX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dogwood Therapeutics does not currently pay a dividend.

Dividend Growth

Dogwood Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for DWTX.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Dogwood Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for DWTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dogwood Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.90% of the stock of Dogwood Therapeutics is held by insiders.

Percentage Held by Institutions

Only 9.05% of the stock of Dogwood Therapeutics is held by institutions.

DWTX Stock Analysis - Frequently Asked Questions

How have DWTX shares performed this year?

Dogwood Therapeutics' stock was trading at $2.49 on January 1st, 2025. Since then, DWTX shares have increased by 95.2% and is now trading at $4.86.

How were Dogwood Therapeutics' earnings last quarter?

Dogwood Therapeutics, Inc (NASDAQ:DWTX) issued its earnings results on Wednesday, August, 13th. The company reported ($1.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by $0.73.

When did Dogwood Therapeutics' stock split?

Dogwood Therapeutics's stock reverse split before market open on Wednesday, October 9th 2024.A 1-25 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Dogwood Therapeutics?

Shares of DWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DWTX
• CIK: 1818844
• Web: www.dwtx.com
• Phone: (866) 620-8655
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Dogwood Therapeutics: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +102.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($18.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -27.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.80
• Quick Ratio: 7.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($7.56) per share
• Price / Book: -0.65

Miscellaneous

• Outstanding Shares: 1,910,000
• Free Float: 1,836,000
• Market Cap: $9.43 million
• Optionable: N/A
• Beta: 1.79